|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,038.00 GBX | -1.83% |
|
-7.41% | +11.70% |
| Capitalization | 81.66B 109B 94.28B 85.11B 149B 10,049B 156B 1,006B 403B 4,819B 410B 402B 17,235B | P/E ratio 2026 * |
12.8x | P/E ratio 2027 * | 11.9x |
|---|---|---|---|---|---|
| Enterprise value | 93.64B 125B 108B 97.59B 171B 11,523B 179B 1,154B 462B 5,526B 471B 461B 19,764B | EV / Sales 2026 * |
2.77x | EV / Sales 2027 * | 2.57x |
| Free-Float |
94.52% | Yield 2026 * |
3.4% | Yield 2027 * | 3.73% |
Last Transcript: GSK plc
| 03-02 | GSK : Sell rating from JP Morgan | ZD |
| 03-02 | Price targets raised for BP and Shell | AN |
| 02-26 | GSK : Jefferies reiterates its Buy rating | ZD |
| 02-26 | GSK : Barclays reaffirms its Sell rating | ZD |
| 02-26 | GSK : Gets a Neutral rating from UBS | ZD |
| 1 day | -1.83% | ||
| 1 week | -7.41% | ||
| Current month | -7.41% | ||
| 1 month | -7.28% | ||
| 3 months | +12.91% | ||
| 6 months | +38.08% | ||
| Current year | +11.70% |
| 1 week | 2,028 |  | 2,196 |
| 1 month | 2,028 | | 2,282 |
| Current year | 1,774 | | 2,282 |
| 1 year | 1,242.5 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 31/12/2025 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 30/04/2023 |
| Chief Tech/Sci/R&D Officer | - | 30/11/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Hal Barron
BRD | Director/Board Member | 64 | 31/12/2017 |
Jonathan Symonds
CHM | Chairman | 68 | 31/08/2019 |
Charles Bancroft
BRD | Director/Board Member | 66 | 30/04/2020 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -1.01% | 3.15% | 26 M€ | |
| +3.24% | 2.97% | 64 M€ | |
| +5.79% | 2.51% | 8 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.83% | -7.41% | +32.86% | +41.35% | 109B | |
| +0.72% | -5.86% | +13.89% | +218.81% | 885B | |
| +0.32% | -3.23% | +44.22% | +56.01% | 579B | |
| -0.96% | -0.85% | +7.38% | +50.47% | 407B | |
| -2.93% | -7.03% | +11.14% | +27.55% | 350B | |
| -1.25% | -5.55% | +22.14% | +55.83% | 302B | |
| -1.85% | -6.70% | +20.11% | +33.64% | 301B | |
| -0.24% | -6.49% | +22.33% | +4.06% | 286B | |
| +0.53% | -4.80% | +13.75% | +61.56% | 199B | |
| -0.83% | -3.37% | +22.59% | +79.29% | 179B | |
| Average | -0.83% | -4.96% | +21.04% | +62.86% | 359.81B | |
| Weighted average by Cap. | -0.51% | -4.68% | +20.65% | +87.64% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.8B 45.26B 39.03B 35.23B 61.64B 4,160B 64.51B 416B 167B 1,995B 170B 166B 7,134B | 35.42B 47.43B 40.89B 36.91B 64.59B 4,359B 67.59B 436B 175B 2,090B 178B 174B 7,475B |
| Net income | 6.31B 8.45B 7.29B 6.58B 11.51B 777B 12.04B 77.76B 31.15B 372B 31.72B 31.04B 1,332B | 6.8B 9.1B 7.85B 7.08B 12.39B 836B 12.97B 83.73B 33.54B 401B 34.15B 33.42B 1,434B |
| Net Debt | 11.98B 16.04B 13.83B 12.49B 21.85B 1,474B 22.87B 148B 59.14B 707B 60.21B 58.93B 2,529B | 9.25B 12.39B 10.68B 9.64B 16.87B 1,139B 17.66B 114B 45.67B 546B 46.5B 45.51B 1,953B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/03/26 | 2,038.00 p | -1.83% | 5,642,056 |
| 05/03/26 | 2,076.00 p | -1.84% | 8,767,151 |
| 04/03/26 | 2,115.00 p | -0.33% | 6,323,059 |
| 03/03/26 | 2,122.00 p | -2.66% | 6,690,212 |
| 02/03/26 | 2,180.00 p | -0.95% | 6,966,860 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition